| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1023: Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments |
|
Medicine details |
|
| Medicine name | elranatamab (Elrexfio®) |
| Formulation | 40 mg/ml solution for injection |
| Reference number | 4943 |
| Indication | Treatment of triple class exposed refractory multiple myeloma |
| Company | Pfizer Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Advice number | ID4026 |
| Date of issue | 17/06/2024 |
| NICE guidance | TA1023: Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments |